Cardiometabolic
The Novo Nordisk Foundation is going global on cardiometabolic disease.
One of the world’s largest foundations is directing more funding beyond Denmark and making obesity, diabetes and cardiovascular disease a central international priority. The investment could fill a dangerous gap in global health. It also raises a harder question: when public systems underfund chronic disease, how much influence should private philanthropy have over what gets…
Pharmacists are becoming the front door for cardiometabolic care. Policy is still treating them like the back office
Dementia prevention has a cardiometabolic blind spot
New nicotine products could become the next major cardiovascular policy failure
Childhood obesity is the next cardiometabolic crisis already unfolding
BMI is not enough. Cardiometabolic risk is hiding in where fat lives
Resistant hypertension may need a diagnostic revolution, not just another drug
When diabetes tech fails, personalised care fails with it
Type 1 diabetes has a kidney problem. FDA is now fast-tracking a possible answer.
Triglycerides are back in the spotlight. Europe is reviewing Sobi’s olezarsen for severe risk.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.